Press releases
- Insulet’s SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
- Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
- Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates
- Insulet to Present at the Jefferies Global Healthcare Conference
- Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year
- Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
More ▼
Key statistics
On Friday, Insulet Corp (P2OD34:SAO) closed at 36.66, -0.60% below its 52-week high of 36.88, set on Jun 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 36.72 |
---|---|
High | 36.88 |
Low | 36.66 |
Bid | 29.88 |
Offer | 35.88 |
Previous close | 36.66 |
Average volume | 11.00 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jul 05 2024 20:54 BST.
More ▼